ClinicalTrials.gg
Not yet recruitingNCT07772115Updated Aug 19, 2026

Occlusal Force and Chewing After Periodontal Therapy

An interventional study of Non-Surgical Periodontal Therapy in Periodontitis, sponsored by Mohammed Bin Rashid University of Medicine and Health Sciences. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Mohammed Bin Rashid University of Medicine and Health Sciences · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Stage III and Stage IV periodontitis are associated with loss of periodontal support, tooth mobility, and impaired oral function, which may affect occlusal force distribution and chewing performance. Although non-surgical periodontal therapy effectively improves periodontal health, its effect on functional occlusal parameters and mandibular movements has not been comprehensively evaluated using digital technologies.

This prospective interventional study will investigate changes in occlusal force distribution and chewing cycle characteristics in patients with Stage III or Stage IV periodontitis before and after non-surgical periodontal therapy. Participants will receive standardized periodontal treatment and will be assessed at baseline, 8-12 weeks after completion of active therapy, and 3 months following re-evaluation. The T-Scan digital occlusal analysis system will be used to record occlusal force distribution, occlusion time, disocclusion time, and force balance. The Modjaw jaw-tracking system will be used to look at chewing cycle characteristics and mandibular movements. The study aims to determine whether periodontal therapy leads to measurable improvements in oral function and to provide objective functional outcome measures that may support periodontal and prosthodontic treatment planning.

02

Conditions studied

  • Periodontitis

Browse trials for

03

In context

Periodontitis

1,231 studies on the registry are indexed under Periodontitis; 295 are open to participants now.

This study's planned enrollment of 30 is below the median of 44 across 846 interventional studies indexed under Periodontitis.

Browse Periodontitis studies →

Lead sponsor

Mohammed Bin Rashid University of Medicine and Health Sciences is the lead sponsor of 20 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18-70 years.
  2. Diagnosis of Stage III or Stage IV periodontitis (Grade A, B, or C) according to the 2018 World Workshop Classification.
  3. Presence of at least 20 natural teeth, including posterior occlusal support.
  4. No periodontal treatment within the preceding 12 months.
  5. Willing and able to attend all scheduled follow-up appointments

Exclusion criteria

Exclusion Criteria:

  1. Systemic conditions known to impair periodontal healing, including:

    • Uncontrolled diabetes mellitus ( >7%)
    • therapy
    • Bisphosphonate therapy
  2. Removable prostheses replacing multiple posterior teeth.
  3. Pregnancy or breastfeeding.
  4. Current occlusal splint wearers.
  5. Planned dental treatment other than periodontal therapy during the study period.
  6. Heavy smokers (>20 cigarettes/day).
  7. Stage I or Stage II periodontitis, gingivitis, or a healthy periodontium.
  8. Severe manual dexterity impairment preventing adequate oral hygiene.
  9. Currently undergoing periodontal treatment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Non-Surgical Periodontal Therapy

    Procedure: Non-Surgical Periodontal Therapy

Interventions

  • ProcedureNon-Surgical Periodontal Therapy

    Standardized non-surgical periodontal therapy consisting of oral hygiene instruction, supragingival debridement, and full-mouth subgingival instrumentation using ultrasonic scalers and hand instruments according to the European Federation of Periodontology (EFP) S3-level clinical practice guideline for Stage III and Stage IV periodontitis.

06

What researchers measure

Primary outcomes

  1. Change in Right-Left Occlusal Force Balance

    Change in right-left occlusal force balance measured using the T-Scan digital occlusal analysis system.

    Time frame: Baseline, 8-12 weeks after completion of non-surgical periodontal therapy, and 3 months after re-evaluation.

Secondary outcomes

  1. Change in Chewing Cycle Characteristics

    Assessment of changes in chewing cycle characteristics measured using the Modjaw jaw tracking system.

    Time frame: Baseline, 8-12 weeks after therapy, and 3 months after re-evaluation.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Pereira LJ, Gazolla CM, Magalhaes IB, Dominguete MH, Vilela GR, Castelo PM, Marques LS, Van Der Bilt A. Influence of periodontal treatment on objective measurement of masticatory performance. J Oral Sci. 2012;54(2):151-7. doi: 10.2334/josnusd.54.151. PubMed 22790407 ↗
  • Palinkas M, Borges TF, Junior MT, Monteiro SAC, Bottacin FS, Mestriner-Junior W, Regalo IH, Siessere S, Semprini M, Regalo SCH. Alterations in masticatory cycle efficiency and bite force in individuals with periodontitis. Int J Health Sci (Qassim). 2019 Jan-Feb;13(1):25-29. PubMed 30842715 ↗
  • Olivieri Q, Maniewicz S, Chebib N, Mojon P, Muller F. The Preferred Chewing Side in Partially Edentulous Patients Is More Related to Residual Dentition Than Hemispheric Laterality. J Oral Rehabil. 2025 Jul;52(7):949-956. doi: 10.1111/joor.13955. Epub 2025 Feb 27. PubMed 40013481 ↗
  • Ikebe K, Matsuda K, Kagawa R, Enoki K, Okada T, Yoshida M, Maeda Y. Masticatory performance in older subjects with varying degrees of tooth loss. J Dent. 2012 Jan;40(1):71-6. doi: 10.1016/j.jdent.2011.10.007. Epub 2011 Oct 21. PubMed 22037296 ↗
  • Barbe AG, Javadian S, Rott T, Scharfenberg I, Deutscher HCD, Noack MJ, Derman SHM. Objective masticatory efficiency and subjective quality of masticatory function among patients with periodontal disease. J Clin Periodontol. 2020 Nov;47(11):1344-1353. doi: 10.1111/jcpe.13364. Epub 2020 Sep 23. PubMed 32892357 ↗
  • Ayuso-Montero R, Mariano-Hernandez Y, Khoury-Ribas L, Rovira-Lastra B, Willaert E, Martinez-Gomis J. Reliability and Validity of T-scan and 3D Intraoral Scanning for Measuring the Occlusal Contact Area. J Prosthodont. 2020 Jan;29(1):19-25. doi: 10.1111/jopr.13096. Epub 2019 Jul 21. PubMed 31270888 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jan 2028, 15 months later.

Of 480 non-industry interventional studies with no phase under Periodontitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 31. This study's planned 15 months is close to that.

Counting every sponsor, half of 494 studies reached it within 16 months; a quarter within 8 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Aug 19, 2026
StartEst.
Oct 6, 2026
Primary completionEst.
Jan 25, 2028
CompletionEst.
Feb 1, 2028
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07772115
Lead sponsor
Mohammed Bin Rashid University of Medicine and Health Sciences
Responsible party
Haitham Elbishari (Asscoaite Professor, Mohammed Bin Rashid University of Medicine and Health Sciences) — Principal investigator
First posted
Aug 19, 2026
Start date
Oct 6, 2026 (estimated)
Primary completion
Jan 25, 2028 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Aug 19, 2026

Study contacts

Haitham Elbishari, PhD
Contact
helbishari@gmail.com
+971529131315

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion